Literature DB >> 22202084

EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas.

Ala-Eddin Al Moustafa1, Amal Achkhar, Amber Yasmeen.   

Abstract

The epidermal growth factor receptor (EGF-R) signaling pathway maintains a balance between cell proliferation, differentiation and apoptosis, and thus it is believed that EGF-R signaling pathways play an important role in the development and progression of several human carcinomas. Epithelial-mesenchymal transition (EMT) describes the dedifferentiation switch between polarized epithelial cancer cells and contractile and motile mesenchymal (invasive) cells during cancer progression and metastasis. Activation of EGF-R signaling regulates EMT-associated invasion and migration in normal and malignant epithelial cells. In contrast, blocking EGF-R and consequently its pathways, by a monoclonal antibody (mAb) or a tyrosine kinase inhibitor (TKI), inhibit cellular migration and invasion, suggesting an essential role for EGF-R inhibitors in the control of cancer metastasis. The purpose of this review is to summarize current information regarding the role of EGF-R signaling on EMT during human cancer progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22202084     DOI: 10.2741/s292

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  39 in total

1.  EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.

Authors:  Zara Zelenko; Emily Jane Gallagher; Irini Markella Antoniou; Deepali Sachdev; Anupma Nayak; Douglas Yee; Derek LeRoith
Journal:  Endocr Relat Cancer       Date:  2016-07-19       Impact factor: 5.678

2.  Incidence of Epstein-Barr virus in Syrian women with breast cancer: A tissue microarray study.

Authors:  Tahar Aboulkassim; Amber Yasmeen; Nizar Akil; Gerald Batist; Ala-Eddin Al Moustafa
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  E5 and E6/E7 of high-risk HPVs cooperate to enhance cancer progression through EMT initiation.

Authors:  Ala-Eddin Al Moustafa
Journal:  Cell Adh Migr       Date:  2015-07-15       Impact factor: 3.405

4.  Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer.

Authors:  Ala-Eddin Al Moustafa
Journal:  Cell Adh Migr       Date:  2013-10-15       Impact factor: 3.405

5.  Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer.

Authors:  Ya-Ting Hsu; Fei Gu; Yi-Wen Huang; Joseph Liu; Jianhua Ruan; Rui-Lan Huang; Chiou-Miin Wang; Chun-Liang Chen; Rohit R Jadhav; Hung-Cheng Lai; David G Mutch; Paul J Goodfellow; Ian M Thompson; Nameer B Kirma; Tim Hui-Ming Huang
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

6.  Epstein-Barr virus and its association with Fascin expression in colorectal cancers in the Syrian population: A tissue microarray study.

Authors:  Noor Al-Antary; Hanan Farghaly; Tahar Aboulkassim; Amber Yasmeen; Nizar Akil; Ala-Eddin Al Moustafa
Journal:  Hum Vaccin Immunother       Date:  2017-03-28       Impact factor: 3.452

Review 7.  Epidermal growth factor signaling in transformed cells.

Authors:  Stephan Lindsey; Sigrid A Langhans
Journal:  Int Rev Cell Mol Biol       Date:  2014-11-18       Impact factor: 6.813

8.  HER-2/Epstein-Barr virus crosstalk in human gastric carcinogenesis: A novel concept of oncogene/oncovirus interaction.

Authors:  Farhan S Cyprian; Noor Al-Antary; Ala-Eddin Al Moustafa
Journal:  Cell Adh Migr       Date:  2017-06-29       Impact factor: 3.405

Review 9.  Signaling mechanisms of the epithelial-mesenchymal transition.

Authors:  David M Gonzalez; Damian Medici
Journal:  Sci Signal       Date:  2014-09-23       Impact factor: 8.192

Review 10.  Review of Integrin-Targeting Biomaterials in Tissue Engineering.

Authors:  Prachi Dhavalikar; Andrew Robinson; Ziyang Lan; Dana Jenkins; Malgorzata Chwatko; Karim Salhadar; Anupriya Jose; Ronit Kar; Erik Shoga; Aparajith Kannapiran; Elizabeth Cosgriff-Hernandez
Journal:  Adv Healthc Mater       Date:  2020-09-16       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.